IDEAYA Biosciences (IDYA) AI Stock Analysis

• Market Cap: $2.56B
• Dividend Yield: N/A
• Average Volume (3M): 1.32M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.55
• Revenue Growth: -41.48%
• EPS Growth: -73.55%
• Country: US
• Employees: 131
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.88
• Shares Outstanding: 87,643,684
• 10 Day Avg. Volume: 1,577,623
• 30 Day Avg. Volume: 1,324,322
• PEG Ratio: -0.11
• Price to Book (P/B): 1.98
• Price to Sales (P/S): 299.87
• P/FCF Ratio: -8.35
• Enterprise Value/Market Cap: 0.48
• Enterprise Value/Revenue: 173.79
• Enterprise Value/Gross Profit: 191.37
• Enterprise Value/Ebitda: -3.18
• 1Y Price Target: $48.13
• Price Target Upside: 69.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 17

• Rating: 56 Neutral
• Price Target: $29.00 ▲(2.04% Upside)

IDEAYA Biosciences' overall stock score is primarily influenced by its financial performance and technical analysis. The company faces financial challenges with declining revenues and consistent net losses, impacting its financial performance score. However, the stock shows positive technical momentum, which partially offsets financial concerns. Valuation remains a challenge due to negative earnings and lack of dividends.

Positive Factors

Strong Clinical Data

The promising clinical trial results for darovasertib in uveal melanoma highlight IDEAYA's potential to address unmet medical needs, enhancing its market position and long-term growth prospects in oncology.

Strategic Partnerships

Strategic partnerships provide IDEAYA with financial support and access to resources necessary for efficient drug development, bolstering its ability to advance its pipeline and enhance long-term growth.

Low Leverage

A low debt-to-equity ratio suggests financial stability and flexibility, allowing IDEAYA to invest in R&D and strategic initiatives without the burden of high-interest obligations.

Negative Factors

Declining Revenue

A significant decline in revenue indicates challenges in commercializing products, which may affect IDEAYA's ability to sustain operations and invest in future growth.

Negative Cash Flow

Negative cash flow from operations suggests that IDEAYA is not generating sufficient cash from its core activities, potentially impacting its ability to fund R&D and operational expenses.

Profitability Challenges

Persistent profitability challenges highlight operational inefficiencies and may hinder IDEAYA's ability to achieve sustainable financial performance, impacting long-term viability.

IDEAYA Biosciences Business Overview & Revenue Model

Company Description

IDEAYA Biosciences (IDYA) is a biotechnology company focused on the discovery and development of targeted therapeutics for cancer and other genetic diseases. The company specializes in precision medicine, leveraging its proprietary drug discovery platforms to identify and develop small molecule therapeutics that target specific genetic mutations and pathways. IDEAYA operates primarily in the oncology sector and is committed to advancing innovative treatment options for patients with unmet medical needs.

How the Company Makes Money

IDEAYA Biosciences generates revenue through a combination of its own product development efforts and strategic partnerships. The company primarily earns money by advancing its pipeline of drug candidates through various stages of clinical trials, leading to potential commercialization. Additionally, IDEAYA enters into collaborations and licensing agreements with larger pharmaceutical companies, which can provide upfront payments, milestone payments based on development progress, and royalties on future sales. These partnerships not only offer financial support but also access to resources and expertise necessary for efficient drug development. The company may also receive funding through grants and investments to support its research initiatives.

IDEAYA Biosciences Financial Statement Overview

Summary

IDEAYA Biosciences faces significant financial challenges with declining revenues and consistent net losses. The company maintains a strong equity position, suggesting stability, but profitability and cash flow constraints pose risks. Strategic improvements are necessary for future growth.

Income Statement

The company has seen a significant decline in revenue over the past year, with a negative growth rate of 70%. Gross profit margin remains at 100% due to no cost of goods sold reported. However, high negative net profit, EBIT, and EBITDA margins reflect operational challenges and lack of profitability.

Balance Sheet

IDEAYA Biosciences maintains a strong equity base, with an equity ratio of 94%. The debt-to-equity ratio is low, indicating minimal leverage, but return on equity is negative due to net losses, highlighting profitability challenges.

Cash Flow

Operating cash flow and free cash flow are both negative, indicating cash burn from operations. However, the company has managed substantial financing activities, improving cash reserves significantly, albeit not enough to cover the free cash flow deficit.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	7.00M	7.00M	23.39M	50.93M	27.94M	19.54M
Gross Profit	6.36M	7.00M	19.38M	48.83M	26.22M	-20.16M
EBITDA	-382.45M	-326.98M	-130.42M	-60.40M	-48.54M	-33.96M
Net Income	-331.03M	-274.48M	-112.96M	-54.81M	-47.53M	-32.27M
Balance Sheet
Total Assets	1.04B	1.12B	649.32M	387.97M	381.35M	298.27M
Cash, Cash Equivalents and Short-Term Investments	669.74M	676.32M	525.11M	373.15M	368.06M	283.58M
Total Debt	26.60M	19.17M	2.87M	3.48M	5.18M	6.72M
Total Liabilities	81.62M	64.94M	28.23M	387.97M	381.35M	298.27M
Stockholders Equity	959.65M	1.06B	621.09M	349.45M	301.51M	198.27M
Cash Flow
Free Cash Flow	-297.26M	-251.44M	-117.59M	-90.62M	-58.42M	54.97M
Operating Cash Flow	-293.70M	-247.58M	-115.22M	-87.17M	-55.78M	55.46M
Investing Cash Flow	-91.41M	-502.56M	-158.46M	-33.40M	-69.67M	-146.24M
Financing Cash Flow	316.61M	677.55M	362.72M	97.17M	145.45M	128.75M

IDEAYA Biosciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 28.42
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IDYA, the sentiment is Positive. The current price of 28.42 is above the 20-day moving average (MA) of 27.68, above the 50-day MA of 26.09, and above the 200-day MA of 22.06, indicating a bullish trend. The MACD of 0.86 indicates Negative momentum. The RSI at 56.85 is Neutral, neither overbought nor oversold. The STOCH value of 53.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IDYA.

IDEAYA Biosciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AGIO	62 Neutral	$2.52B	3.78	64.05%	―	30.57%	―
IDYA	56 Neutral	$2.56B	―	-35.09%	―	-41.48%	-73.55%
TVTX	55 Neutral	$2.45B	―	-705.73%	―	87.94%	57.84%
ARQT	54 Neutral	$2.47B	―	-57.33%	―	99.50%	65.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
BEAM	51 Neutral	$3.02B	―	-41.94%	―	-82.90%	-155.64%
CELC	44 Neutral	$2.97B	―	-134.54%	―	―	-25.61%

IDEAYA Biosciences Corporate Events

IDEAYA Biosciences Presents Promising Phase 2 Data

On October 17, 2025, IDEAYA Biosciences announced positive median overall survival data from its Phase 1/2 trial of darovasertib combined with Pfizer’s crizotinib for first-line treatment of metastatic uveal melanoma, showing a median OS of 21.1 months. Additionally, on October 20, 2025, IDEAYA presented promising Phase 2 data for darovasertib in the neoadjuvant setting of primary uveal melanoma, demonstrating significant tumor shrinkage and eye preservation, with manageable safety profiles.

The most recent analyst rating on (IDYA) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

Ideaya Biosciences Advances IDE849 Study for DLL3-Expressing Tumors

Ideaya Biosciences is conducting a clinical study titled ‘A Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of IDE849 in Patients With DLL3-Expressing Tumors Including Small Cell Lung Cancer.’ The study aims to assess the safety and effectiveness of IDE849, a potential treatment for tumors expressing DLL3, particularly small cell lung cancer (SCLC). This research is significant as it explores new therapeutic options for a challenging cancer type.

IDEAYA Biosciences Reports Promising Phase 1 Data for IDE849

IDEAYA Biosciences, in collaboration with Jiangsu Hengrui Pharmaceuticals, presented promising Phase 1 data for IDE849, a DLL3-targeting TOP1 ADC, at the IASLC 2025 World Conference on Lung Cancer. The trial showed a robust overall response rate and disease control rate in small cell lung cancer patients, with manageable safety profiles across various dose levels. Additionally, IDEAYA shared positive interim results from its Phase 2 trial of darovasertib for primary uveal melanoma, demonstrating significant tumor shrinkage and improved visual outcomes. The company also reported encouraging data from its Phase 1/2 trial of IDE397 combined with Trodelvy in MTAP-deletion urothelial cancer, highlighting a favorable safety profile and notable response rates.

The most recent analyst rating on (IDYA) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

Ideaya Biosciences Advances in Metastatic Uveal Melanoma Treatment Study

Ideaya Biosciences is conducting a clinical study titled ‘IDE196 (Darovasertib) in Combination With Crizotinib Versus Investigator’s Choice of Treatment as First-line Therapy in HLA-A2 Negative Metastatic Uveal Melanoma (DAR-UM-2).’ The study aims to evaluate the efficacy of IDE196 combined with Crizotinib compared to standard treatments for patients with metastatic uveal melanoma, a rare eye cancer. This research is significant as it explores a new potential first-line treatment option for this challenging condition.

IDEAYA Biosciences Licenses Darovasertib to Servier

On August 29, 2025, IDEAYA Biosciences entered into a License Agreement with Les Laboratoires Servier, granting Servier exclusive rights to develop and commercialize darovasertib outside the United States. This agreement includes an upfront payment of $210 million to IDEAYA, with potential additional milestone payments and royalties, extending the company’s cash runway by at least twelve months and funding operations into 2030. The agreement outlines conditions for termination and includes customary transaction provisions.

The most recent analyst rating on (IDYA) stock is a Hold with a $27.00 price target. To see the full list of analyst forecasts on IDEAYA Biosciences stock, see the IDYA Stock Forecast page.

GSK and Ideaya’s Promising Study on Solid Tumors: A Potential Game-Changer?

GlaxoSmithKline (GSK) and Ideaya Biosciences are conducting a study titled A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER). The study aims to evaluate the safety, pharmacokinetics, and preliminary effectiveness of GSK4418959, alone or with a PD-1 inhibitor, in treating aggressive solid tumors with specific genetic traits.

GSK and Ideaya’s Promising Study on Tumor-Reducing Drug GSK4418959

GlaxoSmithKline (GSK) and Ideaya Biosciences are conducting a study titled ‘A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)’. The study aims to evaluate the safety, pharmacokinetics, and preliminary effectiveness of GSK4418959, alone or combined with a PD-1 inhibitor, in reducing tumor size in participants with specific genetic tumor characteristics.

IDEAYA Biosciences Reports Q2 2025 Financial Results

IDEAYA Biosciences, Inc. is a precision medicine oncology company focused on developing transformative therapies for cancer, leveraging expertise in small-molecule drug discovery and antibody-drug conjugates to address molecularly defined solid tumor indications.

Ideaya Biosciences Advances in Ocular Melanoma Treatment with Darovasertib Study

Ideaya Biosciences is conducting a clinical study titled (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma. The study aims to evaluate the effectiveness of IDE196 (darovasertib), a drug designed to treat primary uveal melanoma, a rare eye cancer. This study is significant as it explores a potential new treatment option for a condition with limited therapies.